Sra-333
Balance
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Balance cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NEPENTHE Yolanda Marcen Roman | N/A | D |
DEXKETOPROFEN Yolanda Marcen Roman | N/A | D |
METAMIZOLE Yolanda Marcen Roman | N/A | D |
Same molecule, other indications
Sra-333 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →